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In cancer, epigenetic states are deregulated and thought to be of significance in cancer devel-
opment and progression. We explored DNA methylation-based signatures in association
with breast cancer subtypes to assess their impact on clinical presentation and patient prog-
nosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17
normal breast samples, together with DNA copy number changes and subtype-specific
markers by tissue microarrays. The identified methylation signatures were validated against
a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50method (The Can-
cer Genome Atlas). Selected markers were pyrosequenced in an independent validation
cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The re-
sults demonstrate that DNA methylation patterns linked to the luminal-B subtype are char-
acterized by CpG island promoter methylation events. In contrast, a large fraction of basal-
like tumors are characterized by hypomethylation events occurring within the gene body.
Based on these hallmark signatures, we defined two DNA methylation-based subtypes,
Epi-LumB and Epi-Basal, and show that they are associated with unfavorable clinical param-
eters and reduced survival. Our data show that distinct mechanisms leading to changes in
CpG methylation states are operative in different breast cancer subtypes. Importantly, we
show that a few selected proxy markers can be used to detect the distinct DNA
methylation-based subtypes thereby providing valuable information on disease prognosis.
ª 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).iomedical Research Instit
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 5 5 5e5 6 85561. Introduction adjacent to tumor lesions of patients. The samples were ob-Breast cancer is the most common cancer among women and
ranks among the leading causes of cancer-related deaths
(Hortobagyi et al., 2005). Nevertheless, the over all prognosis
of breast cancer patients has been improving over time, with
marked changes seen since the introduction of adjuvant
chemotherapy and ionizing radiation, coupled with the use
of tamoxifen for patients with hormone receptor-positive tu-
mors and, more recently, trastuzumab for those displaying
overexpression and amplification of the HER-2 oncogene
(Lopez-Tarruella and Martın, 2009). Further improvements in
treatment of breast cancer patients are likely to emerge
from our greater understanding of why only some patients
develop aggressive disease and require adjuvant chemo-
therapy. A major milestone on the way to this goal is the defi-
nition of five biologically and clinically meaningful breast
cancer subtypes based on genome-wide expression analyses:
Luminal-A, Luminal-B, HER-2, Normal-like and Basal-like
(Sorlie et al., 2003; Perou and Børresen-Dale, 2011). An inte-
grated analysis of genome-wide gene expression and copy
number changes was recently carried out to further refine
the previously established breast cancer subtypes (Curtis
et al., 2012).
Different breast cancer subtypes are thought to arise
through different “evolutionary paths” reflecting distinct pat-
terns of mutated cancer genes (Stephens et al., 2012; Cancer
Genome Atlas Network, 2012; Saal et al., 2008; Chin et al.,
2006; Diaz-Cruz et al., 2010; Curtis et al., 2012). Less is known
about the contribution of epigenetic changes to the develop-
ment of biologically distinct breast cancer subtypes. The
epigenome-wide studies so far published on this subject
have either lacked comprehensive profiling technologies or
have not validated any clinical relevance in independent pa-
tient cohorts (Cancer Genome Atlas Network, 2012; Holm
et al., 2010; Bediaga et al., 2010; Fang et al., 2011;
Dedeurwaerder et al., 2011; Hon et al., 2012). Recent efforts
to sequence cancer genomes, including those of breast cancer,
have led to the identification of novel cancer genes and previ-
ously unrecognized signatures of mutational processes
(Stephens et al., 2012; Cancer Genome Atlas Network, 2012).
A recurring theme emerging from these studies is that ac-
quired mutations often affect genes involved in regulating
chromatin dynamics or the processing of epigenetic marks
as seen in various cancer types (Stephens et al., 2012; Cancer
Genome Atlas Network, 2012; Jones et al., 2010; Mamo et al.,
2012). This highlights the importance the epigenome in cancer
development and opens up new potentials for identifying pat-
terns of potential relevance to patient prognosis and personal-
ized medicine (Stefansson and Esteller, 2013; Heyn and
Esteller, 2012).2. Materials and methods
2.1. DNA samples
The study material consisted of 350 primary invasive breast
tumors and 25 normal breast tissue samples obtainedtained from the Department of Pathology, University Hospital,
Iceland. The normal breast tissue samples obtained from the
subset of 25 patients were derived from regions adjacent to
the site of tumor growth. DNA was isolated by the commonly
used phenol-chloroform/proteinase-K method. Patient infor-
mation about the breast cancer samples came from the
population-based Icelandic Cancer Registry (Sigurdardottir
et al., 2012). Data on clinical staging and histological grade
from the Icelandic Cancer Registry were based on analyses
by pathologists at the Department of Pathology, Landspitali
University Hospital. For clinical staging, the TNM system
was followed (tumor size and nodal status), with histological
grade assessed according to the Nottingham system.
Informed consent was obtained from all patients and all
work was carried out according to permissions from the Ice-
landic Data Protection Commission (2006050307) and
Bioethics Committee (VSNb2006050001/03-16).
2.2. DNA methylation analysis
Infinium HumanMethylation450 BeadChips were used to
analyze DNA methylation on a genome-wide scale in the dis-
covery cohort (40 tumors and 17 normal breast tissues). The
450K Infinium microarray data tissue samples have been
deposited to NCBI’s GEO database and can be downloaded
from the following link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token¼en
ijueysntsbvyd&acc¼GSE52865.
The experimental procedures used were those recommen-
ded by the manufacturer (Supplementary Materials &
methods).
The PyroMark Q96 system for pyrosequencing was used to
assess selected markers in the validation cohort. The primer
sequences used in this analysis were designed using Qiagen’s
Pyromark Assay Design 2$0 software (details and primer se-
quences are available in the Supplementary Methods).
2.3. Statistical analyses & bioinformatics procedures
Cluster analysis (carried out in Section 3.1) of the epigenome-
wide data was performed using unsupervised hierarchical
clustering with complete linkage and Manhattan distance on
the top 5000 CpG’s found differentially methylated between
breast tumors and normal breast samples (see further in
Supplementary Methods). We then used the pvclust package
in R to define statistically significant tumor clusters indicating
patterns of potential biological relevance. The DNA methyl-
ation data were then analyzed in a supervised design to iden-
tify sites associated with expression-based subtypes using the
SAMr uni-variate multi-class marker discovery procedure
(samr package in R) wherein permutations are used to esti-
mate the false discovery rate (FDR) (with FDR <5% considered
statistically significant) as carried out in Section 3.2. In this
analysis, we additionally applied a threshold for the signifi-
cant sites usingmean differences on a subtype-by-subtype ba-
sis (also including the group of normal breast tissue samples)
with minimum change of 0.10 in beta-values required in all
subtypeesubtype comparisons for each site (wherein the
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sequence context of differentially methylated genes between
subtypes was then analyzed (carried out in Section 3.2) by hy-
pothesis testing for differences in the counting of CpGs by cat-
egories reflecting functionally relevant sequences, i.e. 1) those
located proximal to the transcription start site (TSS) (inferred
as promoter regions, i.e. CpG’s located within 200 b of the TSS
or within the 50UTR/1stExon), 2) those located more distantly
from the TSS lying within the interval from 200 to 1500 bp up-
stream of the TSS site and 3) those foundwithin the gene body
(excluding the 1st Exon). More detailed analysis in this regards
included the classification of CpG’s within promoter regions
into three distinct groups, i.e. those found within 1) CpG
islands, 2) CpG shores and 3) CpG poor regions. In Section
3.3, we define DNA methylation-based subtypes by a cross-
validation procedure that enables classification of each tumor
according to the identified hallmark signatures (as defined in
Section 3.2). This was carried out using a well-known pattern
recognition algorithm called prediction analysis for microar-
rays (PAM) in a leave-one-out cross-validation design
(Tibshirani et al., 2002).
Tabular data were analyzed by the two-sided chi-squared
contingency test for count data (carried out in Section 3.6).
The KaplaneMeier method was used to generate survival
curves while relative hazards were estimated in multivariate
analyses using the Cox proportional hazards model (carried
out in Sections 3.6e3.7). Patients were followed from the
date of diagnosis until death or last date of follow-up
(December 31st 2009). The outcome was breast cancer-
specific survival, defined as the time from diagnosis to patient
death from breast cancer as registered on death certificates.
Patients who died of causes other than breast cancer were
censored at the date of death. Survival analyses were carried
out in R (survival package). Hazard ratios and the correspond-
ing P-values are reported for eachmethylation-based subtype,
coded as a categorical variable, after having adjusted for the
potential confounding factors of patient age and year of
diagnosis.3. Results
3.1. Genome-wide DNA methylation patterns and breast
cancer subtypes
CpGs that were differentially methylated between breast tu-
mors and normal breast tissues were identified and explored
in relation to biologically relevant subtypes by cluster analysis
(Figure 1A; Supplementary Figure 1). This revealed a distinc-
tive DNA methylation pattern (significant at AU > 95%; by
the pvclust method) enriched with tumors of the Luminal-B
(LumB) phenotype (indicated as “Cluster 1”, Figure 1A). These
tumors show extensive DNA methylation of CpG islands
implying that they have acquired a methylator phenotype.
Interestingly, these characteristics did not appear to be
restricted to LumB tumors as a few members of other sub-
types also displayed this pattern, whereby one tumor was
classified as Luminal-A (LumA) and the other as HER2 (see in
“Cluster 1”; Figure 1A). The DNA methylation patterns of
most, but not all, Basal-like tumors were also distinctive(AU > 95%; indicated as “Cluster 2”, Figure 1A) in that the
changes affected a different set of CpGs from those affected
in most other tumors. In contrast, HER2 and Luminal-A
(LumA) breast tumors were more heterogenous in terms of
their DNA methylation patterns as these tumors were more
widely dispersed throughout the cluster dendrogram. Indeed,
only a small subset of the LumA breast tumors (four out of
twelve) showed evidence of a distinctive (i.e., statistically sig-
nificant; AU> 95%) pattern of DNAmethylation changes (indi-
cated as “Cluster 3”, Figure 1A), emphasizing the biological
heterogeneity within this subtype (Supplementary Figure 1).
In summary, this analysis supports the notion that CpG
methylation changes observed on a genome-wide scale are
systematically linked to distinct breast cancer subtypes, in
particular the LumB and Basal-like subtypes (Supplementary
Table 1).
3.2. Distinct epigenomic characteristics between breast
cancers of the Luminal-B and basal-like subtypes
Given the observed potential of DNA methylation changes for
identifying biologically aggressive breast cancer subtypes,
notably those identified as LumB and Basal-like (as revealed
through the cluster analysis), we derived methylation signa-
tures for each subtype through a multi-class procedure (uni-
variate) with permutations to adjust for multiple hypothesis
testing (Figure 1B; Supplementary Figure 2). The subtype-
specific CpG’s identified through this procedure were vali-
dated against an independent cohort (The Cancer Genome
Atlas; TCGA) wherein breast cancer subtypes have been anno-
tated for each tumor by the PAM50 assay using expression ar-
rays (as described in Parker et al., 2009). The overlap between
CpG’s identified as specific for the expression-based subtypes
in our cohort (PEBC) and the TCGA cohort is shown in
Figure 2A. This analysis revealed consistent changes specific
for breast cancers of the LumB and Basal-like subtypes with
254 and 202 CpG’s found specific for LumB and Basal-like
breast cancers, respectively, in both cohorts (Figure 2A;
Supplementary Table 2). In contrast, breast cancers of the
LumA and HER2 subtypes showed very limited or no overlap
at all (Figure 2A). The validated set of subtype-specific CpG’s
are displayed in Figure 2B. Here, we note that while most
LumB tumors appear to robustly display the methylation
pattern associated with the LumB subype, a subset of LumB
tumors do not and, furthermore, an appreciable number of
LumA and HER2 tumors appear to display LumB-
methylation characteristics (Figure 2B). In contrast, the
Basal-like specific CpG methylation pattern appears specific
for basal-like tumors - especially when looking at the hypo-
methylated CpG’s (Figure 2B). Nonetheless, it is clear that
some basal-like tumors do not conform to the basal-like
methylation pattern, i.e. a few basal-like tumors appear to
be “out of place” (Figure 2B). These observations are addressed
and extended further in Section 3.3.
The resulting DNA methylation signatures for LumB and
Basal-like tumors, based on the validated catalogue of
subtype-specific CpG’s (i.e. the overlapping 254 LumB specific
CpG’s and 202 Basal-like specific CpG’s), were analyzed further
in terms of functionally relevant DNA sequence elements.
This analysis revealed that the LumB signature
Figure 1 e DNA methylation changes in breast tumors are non-random and define patterns correlated with clinically and biologically relevant subtypes. A) Cluster analysis of differentially methylated
CpGs between breast cancers and normal breast tissue (the top 5000 most significant CpGs). Tumor characteristics (by columns on top of the heat-map) in terms of breast cancer subtype along with the
presence of acquired mutations in the TP53 gene are displayed together with the CpG context (by rows on the left-hand side) according to the color scheme shown at the right-hand side and bottom of the
figure, respectively. The statistically significant tumor patterns/clusters (identified by the pvclust method in R) are shown as colored bars immediately below the dendrogram. B) The top 10 significant
CpG’s specifically characterizing each of the four “core” subtypes are shown, i.e. the LumA, LumB, HER2 and Basal-like subtypes. Note, 5NP (i.e. unclassified tumors due to negativity for all five
phenotypic markers, i.e. ER, PR, HER2, CK5/6 and EGFR) and breast tumors with unknown subtype information are grouped together as 5NP/NA and were not included in this analysis. The normal
breast tissue samples are shown and indicated in black on top of the heat-map. Note, the heat-map colors reflect beta-values representing the degree of methylation from low to high as green to red,

































Figure 2 e Validation of CpG methylation patterns associated with breast cancer subtypes. A) The subtype-specific CpG methylation changes
identified in relation to each of the four breast cancer subtypes (LumA, LumB, HER2 and Basal-like) were validated in an independent cohort
obtained through the Cancer Genome Atlas. The overlap, i.e. the number of CpG’s consistently associated with each of the subtypes in both the
TCGA and PEBC cohorts, is indicated by an arrow. B) The validated set of 254 LumB and 202 Basal-like specific CpG’s shown in both cohorts,
i.e. the PEBC cohort (left) and the TCGA cohort (right). The expression-based subtypes are shown on top of the heat-maps according to the color
scheme displayed at the bottom of the figure. Note the heterogeneity among LumB breast tumors, i.e. although most LumB tumors appear to
robustly display the LumB-methylation pattern there are still those that do not and, furthermore, some of the tumors classified as either LumA or
HER2 by expression analysis appear to display the LumB-associated CpG methylation pattern. The CpG methylation states identified as
methylated or hypomethylated (relative to normal breast tissue samples) are indicated on the right hand side of the heat-maps. The heat-map
colors reflect beta-values representing the degree of methylation from low to high as green to red, respectively (wherein black represents
heterogenous/hemi-methylation), as shown on the scale at the bottom-right hand side of the figure.
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quences (54%, 137 of 254; see Figure 3A) whereas the Basal-
like signature predominantly involved hypomethylation
events occurring in gene body regions (26%, 53 of 202; see
Figure 3B). As this analysis only includes the catalogue of vali-
dated CpG’s between the two cohorts (i.e. the overlap between
subtype-specific CpG’s identified in both the PEBC and TCGA
cohorts), the LumA and HER2 subtypes were excluded due to
the lack of consistently associated CpG’s (see further in
Figure 2A).
In exploring events involving CpG promoter methylation
further, i.e. focusing only on promoter regions, we found
that promoter methylation events within the LumB signature
almost exclusively involve CpG islands rather than shores
(Figure 3C). In contrast, Basal-like breast cancers are more or
less equally likely to involve CpG shores and other CpG poor
promoter regions (Figure 3C). We further demonstrate that
the 90 genes uniquely affected by promoter methylation
over the 137 CpG’s consistently identified in association with
the LumB subtype (see Supplementary Table 2) are signifi-
cantly enriched as targets of the Polycomb group repressor
complex 2 (PCR2) in embryonic stem cells (Padjusted < 0.01;
Figure 3D). Specifically, 31 out of these 90 genes (31 of 90;34.4%) are known targets of the PCR2 complex. This fraction
(34.4%) is significantly higher than can be expected by chance
assuming that the list of known PCR2 target genes encom-
passes 652 genes (Padjusted < 0.01; Figure 3D; see also
Supplementary Methods). The same was not true for Basal-
like breast cancers regardless of whether we based the anal-
ysis on the catalogue of 19 validated promoter associated
CpG’s (i.e. the catalogue of 19 promoter methylation linked
CpG’s associated with Basal-like tumors in both PEBC &
TCGA cohorts), or the catalogue of “non-validated” promoter
associated CpG’s (i.e. those identified as Basal-like specific
events in either the PEBC or TCGA cohorts separately; data
not shown).
3.3. DNA methylation-based definition of breast cancer
subtypes
Given the distinctive epigenomic features observed in associ-
ation with LumB and Basal-like breast cancers, i.e. CpG island
promoter methylation and gene body hypomethylation in
LumB and Basal-like tumors, respectively, we set out to deter-
mine how unique these “hallmark features” are to each of the
two expression-based subtypes. This was carried out using a
Figure 3 e CpG sequence characteristics of the identified subtype-specific methylation changes. A) The validated DNA methylation signatures
specific for LumB (254 CpG’s) and B) Basal-like (202 CpG’s) breast cancers differ significantly with respect to the sequence context in which CpG
methylation changes tend to occur. The P-values corresponding to a chi-squared contingency tests indicate “hallmark” features statistically
significant for each of the two subtypes involving promoter methylation events for the LumB subtype (c2 [ 14.7; P-value [ 0.002) and gene body
hypomethylation for the Basal-like subtype (c2 [ 9.8; P-value[ 0.02). The percentages are computed over all subtype-specific CpG’s wherein the
total number was 254 CpG’s for the LumB subtype and 202 CpG’s for the Basal-like subtype (with the number of CpG’s given for each count; on
the top of each bar). The categories analyzed include 1) gene promoter regions, 2) L1500 bp TSS indicative of CpG sites located between 1500 bp
and 200 bp upstream of transcription start sites (TSS); thus representing potential cis regulatory regions without involving the promoter region and
3) the gene body sites representing sequences located within the gene body. Lastly, the “other” category predominantly represents CpG’s found in
intergenic regions, i.e. those found outside of the cis regulatory regions (i.e. those not included in the categories of either promoter or L1500 bp
CpG’s) while also not included in the gene body category. C) Promoters displaying methylation in association with either the Basal-like or LumB
subtypes analyzed in terms of CpG islands, CpG shores or CpG poor promoter regions. The percentages are computed for each subtype separately
(i.e. Basal-like and LumB) based on the total number of promoter methylation events specific for each of the two subtypes, i.e. a total of 19 CpG’s
for the Basal-like subtype and 137 CpG’s for the LumB subtype. D) The genes affected by promoter methylation within the validated subtype-
specific signatures analyzed in terms of whether or not they have been identified as targets of the Polycomb group repressor complex 2 (PRC2). The
P-values were derived from Fisher’s exact hypothesis testing and the threshold line indicated (grey line) reflects the Padjusted < 0.01 significance
level after Bonferroni adjustment for multiple hypothesis testing.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 5 5 5e5 6 8560well-established algorithm for pattern recognition, by which
we determined the “degree of similarity” (reflected in the
cross-validation probabilities) for each tumor to the signa-
tures of LumB-associated CpG island promoter methylation
(consisting of 129 CpG’s as shown in Figure 3C) and Basal-
like associated gene body hypomethylation (consisting of 53
CpG’s as shown in the lower panel of Figure 3B). In this anal-
ysis, we found that the signature of LumB-associated CpG is-
land promoter methylation events effectively characterized
most, but not all, of the LumB tumors (6 of 7; 85.7%) while
also characterizing two tumors of the LumA (2 of 11; 18.2%)
and one of the HER2 subtype (1 of 3; 33.3%) (Figure 4A). In sum-
mary, out of the 40 tumors analyzed in our cohort, 10 tumors
(10 of 40; 25%) robustly displayed the LumB-signature. Similar
results were obtained based on the analysis of the TCGA
cohort, wherein we find that the majority but not all of the
LumB tumors robustly display the LumB-associated CpGisland promoter methylation signature (33 of 46; 71.7%)
(Figure 4A). While, at the same time, a few members of the
LumA (29 of 108; 26.8%) and HER2-enriched subtype (4 of 14;
28.6%) also display the LumB-signature. In summary, out of
the 212 tumors analyzed in the TCGA cohort, 66 tumors (66
of 212; 31.1%) robustly displayed the LumB-associated signa-
ture of CpG island promotermethylation events. The presence
of LumB-linked methylome characteristics in an appreciable
proportion of LumA and HER2 associated tumors provides
the basis for defining a novel subtype hereafter referred to
as Epi-LumB (the “Epi” prefix indicating its epigenetic nature).
In looking at the gene body hypomethylation signature
associated with the Basal-like subtype, we found that most
(though not all), of the basal-like tumors in our cohort robustly
display this signature (11 of 14; 78.6%) (Figure 4B). In summary,
we find no members of any other subtype displaying the
basal-like associated gene body hypomethylation signature
Figure 4 e The definition of DNA methylation-based subtypes in breast tumors. A) Cross-validated probability values derived from a well-
established pattern recognition algorithm (PAMr implemented in R) indicating how robustly each tumor displays the validated signature of
LumB-associated CpG island promoter methylation events (based on the validated catalogue of LumB-associated CpG island promoter
methylation events, i.e. the 129 CpG’s indicated in Figure 3C). The barplots show the probability values on the y-axis for each tumor ordered on
the x-axis from left to right according to the probability values from low to high, respectively, for each of the two cohorts i.e. the PEBC cohort
(barplot on the left) and the TCGA cohort (barplot on the right). Tumors scoring positive for this signature have a cross-validated probability
>0.50 as indicated by the dashed line over each of the two barplots. The color of each bar (representing tumors) is indicative of the expression-
based subtype as given at the bottom of the figure. B) The cross-validated probability values derived from PAMr indicating how robustly each
tumor displays the Basal-like associated gene body hypomethylation signature (based on the 53 CpG’s as indicated in the lower panel of Figure 3B)
shown for both the PEBC (left) and TCGA cohorts (right). C) DNA methylation data over the validated catalogue of 129 “hallmark” CpG’s
characteristic of LumB tumors (i.e. those identified within CpG island promoters in association with the LumB subtype consistently in both the
PEBC and TCGA cohorts) shown with respect to the novel Epi-LumB subtype. The expression-based subtypes are shown according to the color
scheme displayed at the bottom of the figure. D) Similarly, the DNA methylation data over the validated catalogue of 53 “hallmark” CpG’s
characteristic of Basal-like tumors (i.e. gene body CpG’s consistently associated with Basal-like tumors in both the PEBC and TCGA cohorts) are
shown with respect to the novel Epi-Basal subtype.
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analyzed in the PEBC cohort, 11 displayed this basal-like
signature (11 of 40; 27.5%). In the TCGA cohort, we similarly
find that most but not all of the basal-like tumors (30 of 39;
76.9%) robustly display the basal-like associated gene body
hypomethylation signature. In this cohort, only one member
of another subtype displayed this signature, i.e. a HER2-
enriched tumor (1 of 14; 7.1%). Thus, to summarize, out of
the 212 tumors analyzed in the TCGA cohort, a total of 31
robustly displayed the basal-like gene body hypomethylation
signature (31 of 212; 14.6%). Given the unique methylome
characteristics, i.e. gene body hypomethylation, we refer tothe group of tumors that robustly display the gene body hypo-
methylation signature as the Epi-Basal subtype. The CpG
methylation signatures leading to the classification of tumors
as either Epi-LumB or Epi-Basal are shown in Figure 4C and D,
respectively.
3.4. Gene promoter methylation events affecting known
cancer genes found in association with the DNA
methylation-based subtypes
We found that the inherent propensity of Epi-LumB tumors to
acquire CpG island promoter methylation events affected a
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 5 5 5e5 6 8562subset of previously established tumor suppressor genes
(based on the catalogue of 716 TSG, see Zhao et al., 2013) of
which at least five are shown to be strongly down-regulated
upon CpG promoter methylation, i.e. L3MBTL4, ID4, IRX1,
PTCH2 and RASSF10 (Table 1). The Epi-Basal subtype, in
contrast, was not found to be associated with CpG methyl-
ation over the promoter region of known tumor suppressor
genes. We note, however, that the analysis of both cohorts
supports the observation that basal-like breast cancers,
regardless of whether or not they are Epi-Basal, significantly
associate with promoter methylation of the BRCA1 gene - a
central tumor suppressor gene in breast cancer (data no
shown). BRCA1 promoter methylation, however, does not
hold significantly associated with the Epi-Basal subtype
(data not shown). This event, i.e. BRCA1 promoter methyl-
ation, is therefore likely to be more specifically related to the
basal-like phenotype rather than the gene body hypomethyla-
tion phenotype.3.5. Distinct tumor evolutionary paths in association
with Epi-LumB and Epi-Basal tumors
The different patterns, or signatures, of changes in CpG
methylation states are indicative of divergent evolutionary
paths. To test this hypothesis, we studied the patterns of
DNA copy number changes in the same cohort of breast tu-
mors as those analyzed using the 450K Infinium methylation
method. Here, we identified highly recurrent copy number
changes that were significantly associated with Epi-LumB tu-
mors in both cohorts involving deletions over chromosomes
13q and 16p, together with copy number gains ofTable 1 e Epi-LumB specific CpG methylation events (significant
at the <1% FDR in both the PEBC and TCGA cohorts) were
found to affect a subset of previously known tumor suppressor genes
(based on the catalogue of 716 TSG’s). The statistics shown describe
the relation between CpG methylation and expression over Epi-
LumB-associated TSG’s in the TCGA cohort where data was
available on both CpG methylation and expression (by RNA
sequencing) for 731 tumors and 82 normal breast tissue samples.
Statistically significant hits are shown (including a minimum









cg14352983 L3MBTL4 0.264 2.667 4.96E-55
cg08336641 L3MBTL4 0.259 3.004 1.12E-53
cg14155416 L3MBTL4 0.255 2.621 7.90E-53
cg12924825 L3MBTL4 0.253 2.902 2.17E-52
cg18556788 L3MBTL4 0.245 2.652 2.02E-50
cg17688525 L3MBTL4 0.241 2.710 1.43E-49
cg03715143 ID4 0.238 2.850 8.89E-49
cg09232937 IRX1 0.191 6.137 2.08E-38
cg05724871 L3MBTL4 0.177 2.625 1.99E-35
cg14271531 ID4 0.147 2.676 5.32E-29
cg21167628 PTCH2 0.116 2.028 7.70E-23
cg20918243 RASSF10 0.109 9.006 2.33E-21
cg10530883 IRX1 0.106 5.251 8.22E-21chromosomes 12q, 17q and 20q (Figure 5A). In this analysis,
we identified subtype-specific events for Epi-LumB tumors
involving either DNA copy number loss or CpG promoter
methylation over DZIP1, TNFSF11, ZIC5, COL4A2, COL4A1 and
PCDH8 indicating candidate tumor suppressor genes
(Figure 5A; Supplementary Figure 3). Of these genes, DZIP1
and COL4A2 show a significant relation between promoter
methylation and down-regulated expression based on data
from the TCGA cohort (data not shown).
As expected, given the overlap with the basal-like subtype,
we found that tumors of the Epi-Basal subtype displayed high-
ly aberrational landscapes of DNA copy number changes.
Many of the DNA copy number changes observed in Epi-
Basal tumors were recurrent such as deletions over 4p, 5q,
12q and 17p as well as copy number gains over 7q, 9p and
12p (Figure 5B). Here, subtype-specific events involving either
DNA copy number loss or CpG promoter methylation were
found to involve TENC1, RARA, PCDHB11, PCDHB14, PCDHGA2
and PCDHGB2 indicative of candidate tumor suppressor genes
in this context (Figure 5B; Supplementary Figure 3). Based on
the TCGA cohort, the TENC1, PCDHB11 and PCDHGA2 genes
show a clear relation between promoter methylation and
down-regulated expression (data not shown).
3.6. The clinical relevance of DNA methylation-based
subtypes
To determine the clinical relevance of the DNA methylation-
based subtypes (the Epi-LumB and Epi-Basal subtypes), we
developed locus-specific assays for analyzing a few selected
markers that could serve as proxies for tumor classification.
We selected TTBK1, ZNF132 and KCNA3 from the catalogue
of top significant CpG island promoter methylation events
(only taking into account CpG’s located in gene promoters
containing CpG islands) associated with Epi-LumB tumors
(Supplementary Table 3). In designing an assay for the Epi-
Basal subtype, there are a number of problems that arise
with detecting gene body hypomethylation including the
identification of a region that is recurrently hypomethylated
while, at the same time, the change from high to low levels of
methylation (in normal tissue compared with tumors,
respectively), would need to be substantial to enable accurate
and sensitive detection in clinical samples. The presence of
stromal cells, the normal breast epithelial tissue and lym-
phocytes in such samples all add to the difficulties with
this type of analysis. Although these factors were not an
obstacle in discovering the gene body hypomethylation
phenotype (i.e. in relation to the Epi-Basal subtype), see
Supplementary Figure 4, they can lead to unreliable results
in the clinical setting. For these reasons we selected CpG pro-
moter methylation events, rather than body hypomethyla-
tion events, identified as top significant markers in
association with tumors classified as Epi-Basal. As this assay
does not directly measure the phenotype of interest, i.e. gene
body hypomethylation, it should be understood that it may
simply reflect another way for classifying basal-like breast
cancers (an alternative to expression analyses) e especially
since nearly all of the basal-like breast cancers included in
the discovery cohort were found to display the gene body
hypomethylation phenotype as revealed in Figure 4B and D.
Table 2 e DNA methylation defined subtypes in an independent
cohort validating the relation to the classification of breast cancers
according to expression-based subtypes.a
Basal-
like
HER2 LumA LumB 5NPb Total
Epi-LumB 2 (8%) 2 (8%) 7 (29%) 11 (46%) 2 (8%) 24 (100%)
Epi-Basal 10 (40%) 1 (4%) 6 (24%) 7 (28%) 1 (4%) 25 (100%)
Other 0 0 25 (62%) 14 (35%) 1 (3%) 40 (100%)
X2 ¼ 31.0;
P ¼ 0.00014
a Information on expression-based subtype classification was
available in 89 of the tumors included in the validation cohort.
b 5NP represents unclassified tumors due to negativity for the five
phenotypic markers ER, PR, HER2, CK5/6 and EGFR.
Figure 5 e Patterns of DNA copy number changes associated with Epi-LumB and Epi-Basal tumors revealing divergent tumor evolutionary paths
and candidate tumor suppressor genes. A) Frequencies of DNA copy number gains and losses in Epi-LumB tumors are displayed as proportions on
the y-axis (positive and negative signs represent gains and losses, respectively) according to genomic position along the x-axis from p-arm to q-arm
(left to right, respectively) for all 23 chromosomes. The blue and red lines are frequencies derived from the PEBC and TCGA cohorts, respectively.
The bars (black) on top and below the frequency plot indicate positions wherein copy number gains and losses, respectively, were found to be
associated with Epi-LumB tumors (comparing Epi-LumB against all other tumors). Only regions wherein the statistical significance achieved less
than 5% FDR in both the PEBC and TCGA cohorts are shown. A subset of the genes found within significant regions of copy number loss were
also found to be promoter methylated in association with the Epi-LumB subtype. The identity of these candidate tumor suppressor genes are given
below the frequency plot. B) Event frequency plot for Epi-Basal tumors (upper), with the corresponding significance analysis (black bars above and
below the frequency plot indicative of significant copy number gains and losses, respectivley). Epi-Basal associated promoter methylation events
(gene symbols) found within significant regions of copy number losses are shown.
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DNA methylation-based assay for the Epi-Basal subtype can
improve the prognostic value for this subtype contrasted
against the expression-based definition alone. Based on this
reasoning, we selected ZNF671 and TENC1 promoter methyl-
ation as putative markers of Epi-Basal breast cancers from
the top promoter methylation events identified as signifi-
cantly associated with tumors classified as Epi-Basal
(Supplementary Table 3). Although the selection of subtype-
specific methylation markers was based on the top signifi-
cant CpG’s indicative of different breast cancer subtypes
(not taking into account their effects on gene expression),
we find that the proxy markers KCNA3, ZNF132, TENC1 and
ZNF671 are down-regulated in association with promoter
methylation based on RNA sequencing and methylation
data from the TCGA cohort (Supplementary Figure 5).
Pyrosequencing was then used to analyze the selected
proxy markers for Epi-LumB and Epi-Basal tumors in an inde-
pendent validation cohort of primary breast tumor samples
from 310 patients. The Epi-LumB subtype was then assigned
to tumors displaying methylation over the promoter region
of two out of the three surrogate markers (TTBK1, ZNF132
and KCNA3). The Epi-Basal subtype was then assigned to tu-
mors negative for the Epi-LumB phenotype while positive for
methylation of either TENC1 or ZNF671. In support for the val-
idity of this classification system, we find that LumB tumors
are enriched within the Epi-LumB subtype while basal-liketumors are enriched within the Epi-Basal subtype (Table 2).
The Epi-LumB and Epi-Basal subtypes, defined according to
this proxy-based classification system, were both found to
be significantly associated with greater tumor size and poorly
differentiated phenotypes (Table 3). Importantly, the results
revealed significantly shorter survival times for patients that
develop Epi-LumB subtype breast tumors after adjustment
for tumor size, the presence of lymph node metastases along
with age and year at diagnosis (Hazards-ratio¼ 1.83; P¼ 0.035)
(Figure 6A).
Table 3 e The clinical relevance of Epi-LumB and Epi-Basal
tumors, defined according to selected proxy markers, analyzed with
respect to parameters of clinical staging (tumor size and nodal
metastasis status) and degree of differentiation (histological grade).
Tumor size T1a-c T2 e T3 Total
Epi-LumB 18 (26%) 52 (74%) 68 (100%)
Epi-Basal 17 (30%) 40 (70%) 56 (100%)
Other 46 (52%) 42 (48%) 88 (100%)
X2 ¼ 13.7; P ¼ 0.0010
Nodal metastases Negative Positive Total
Epi-LumB 23 (35%) 43 (65%) 64 (100%)
Epi-Basal 19 (36%) 34 (64%) 52 (100%)
Other 37 (49%) 38 (51%) 75 (100%)
X2 ¼ 3.8; P ¼ 0.15
Histological grading 1D/2D 3D Total
Epi-LumB 12 (32%) 25 (67%) 35 (100%)
Epi-Basal 11 (32%) 23 (68%) 33 (100%)
Other 47 (78%) 13 (22%) 54 (100%)
X2 ¼ 27.6; P < 0.0001
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 5 5 5e5 6 85643.7. Improved identification of highly aggressive breast
cancers by combining methylation- and expression-based
subtype definitions
We find that breast cancer-specific survival times in LumB
breast cancer patients do not differ depending on whether
or not the tumors are positive for the Epi-LumB phenotype
(data not shown). Similarly, survival of patients with basal-
like breast cancers does not differ depending on whether or
not the tumors are positive for the Epi-Basal phenotype
(data not shown). These results indicate that the prognostic
value associated with methylation- and expression-based
breast cancer subtype definitions do not differ significantly
e although we note that the number of patients in the inde-
pendent cohort with available information on both definitions
entails limited statistical power.
Based on these results, we addressed the question of
whether methylation markers can improve the prognostic
value associated with standard expression-based definition
of breast cancer subtypes. This was carried out using multi-
variate Cox proportional hazards regression analyses in estro-
gen positive and negative disease separately to then test
whether the addition of the Epi-LumB and Epi-Basal subtype
definitions, respectively, would provide additional informa-
tion on disease prognosis beyond that provided by
expression-basedmarkers alone. Using this approach, we first
focused exclusively on estrogen-receptor (ER) positive disease
and show that ER þ tumors displaying either the LumB
expression-based phenotype or positivity for the Epi-LumB
markers (grouped together as “high-risk luminal”) have
approximately 5-fold increased risk for breast cancer-
specific death (Hazards ratio ¼ 4.63; P ¼ 0.035) and, impor-
tantly, this effect was independent of the LumB expression-
based phenotype alone in a model allowing adjustment for
age- and year at diagnosis (Figure 6B). In estrogen-receptor
negative disease, the low number of ER-tumors did not reveal
formal statistical significance (Figure 6C). However, we note
that a trend can be observed wherein ER-tumors that are pos-
itive for either the basal-like expression markers (CK5/6 or
EGFR positivity) or the Epi-Basal markers (grouped togetheras “high-risk non-luminal“) are marginally associated with
approximately 10-fold increased risk for breast cancer-
specific death independently of the expression-based defini-
tion for basal-like cancers alone in a model with adjustment
for age and year at diagnosis (Hazards ratio ¼ 9.79; P ¼ 0.079)
(Figure 6C, lower panel).4. Discussion
In this report we identify DNAmethylation signatures that are
associated with biologically distinct breast cancer subtypes.
We show that the signatures identified are characterized not
only by differences in the catalogue of genes affected but
also in the CpG context, i.e. in the DNA sequences that tend
to undergo changes in methylation states. This involves a
significantly higher propensity for CpG island methylation at
promoter sequences in breast tumors of the Luminal-B sub-
type (LumB), whereas gene body hypomethylation events
characterize those of the Basal-like subtype. This suggests
that the mechanisms predominantly responsible for changes
in the landscape of breast cancer methylomes differ between
biologically distinct cancer subtypes. Based on these results,
we explored the clinical relevance of defining novel DNA
methylation-based subtypes according to the hallmark fea-
tures associated with each of the two identified signatures.
To address this, we developed locus-specific assays for
selected proxy markers to identify 1) the signature of LumB-
associated CpG island promoter methylation events defining
the Epi-LumB subtype, and 2) the signature of Basal-like asso-
ciated gene body hypomethylation events defining the Epi-
Basal subtype. The analysis of these selected proxy markers
in a larger independent cohort of patients reveals rapid dis-
ease progression in the context of poorly differentiated phe-
notypes in tumors classified as either Epi-LumB or Epi-Basal.
The clinical importance of this finding relates to the identifica-
tion of patients that will require adjuvant treatment options
and close follow-up. The failure to identify patients with
aggressive disease can result in sub-optimal outcomes and,
possibly, patient death that could otherwise have been
avoided or substantially delayed. In turn, it is well established
that a considerable fraction of patients are being unnecessar-
ily treated with cytotoxic drugs. The novel DNA methylation-
defined subtypes described here could therefore be helpful as
prognostic parameters for making decision regarding the
treatment of breast cancer patients.
It has previously been shown that CpG island promoter
methylation events in cancers tend to affect genes regulated
by the Polycomb repressor group complex 2 (PRC2) marked
for repression by histone modifications involving the
H3K27Me3 mark in embryonic stem cells (Vire et al., 2006).
Our results support this finding and demonstrate that this
property characterizes the majority of breast cancers classi-
fied as LumB. In contrast, we find that the tendency to display
CpG island promoter methylation events does not specifically
characterize Basal-like tumors. These tumors, however, are
preferentially characterized by gene body hypomethylation
events suggesting that a fundamentally different mechanism
is effectively more responsible for driving epigenetic changes
in breast cancers of the Basal-like subtype. The gene bodies of
Figure 6 e Breast cancer-specific survival analysis with respect to the novel DNA methylation defined subtypes, i.e. the Epi-LumB and Epi-Basal
subtypes. A) Patients with breast tumors classified as either Epi-LumB or Epi-Basal on the basis of proxy CpG methylation markers (see Section
3.6 for details) are associated with reduced time to death due to breast cancer (i.e. breast cancer-specific death). The lower panel displays a
multivariate Cox’s proportional hazards modeling of the survival data wherein the Epi-LumB subtype was found to be an independent prognostic
factor after adjustment for tumor size, lymph node metastases and age- and year at diagnosis. B) In analyzing a subset of the tumors wherein
information on hormone receptor status (along with subtype-specific markers) was available, we show that ER positive tumors classified as either
Epi-LumB (based on proxy-methylation markers) or LumB (based on the Ki-67 expression marker) represents an improvement above the LumB
definition alone for predicting reduced time to breast cancer-specific death. The lower panel shows the multivariate Cox’s proportional hazards
regression model for ER positive tumors classified as either Epi-LumB (based on the proxy-methylation markers) or LumB (based on high Ki-67
expression) referred to as “high-risk luminal tumors”, demonstrating the superior prognostic value in combining epigenetic and expression data
above that of expression data alone. C) The Epi-Basal subtype combined with the basal-like expression-based definition (using EGFR and CK5/6)
was not significantly associated with reduced time to breast cancer-specific deaths in ER negative breast cancers. However, as shown in the lower
panel, the combination of epigenetic and expression data provides superior prognostic value of marginal statistical significance above that of
expression data alone. Here, ER negative tumors classified as either Epi-Basal (on the basis of proxy-methylation markers) or basal-like (based on
expression of either EGFR or CK5/6), referred to as “high-risk non-luminal tumors” remain marginally significant for predicting breast cancer-
specific deaths while the basal-like definition alone does not hold significant.
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ated (Jones, 2012). The functional relevance of gene body
hypomethylation events is still unclear, however, a recent pa-
per describes hypomethylated gene bodies as a characteristic
of repressed genes in a cancer cell linemodel (Hon et al., 2012).
Further support for a causative relation between hypomethy-
lation of gene bodies and loss of expression has been reportedby other research groups (Yang et al., 2014; Varley et al., 2013).
Thus, loss of gene body methylation described here as a hall-
mark feature of Basal-like tumors could represent a mecha-
nism of gene silencing.
By using data on DNA copy number changes, we identified
genes of potential interest as tumor suppressors in the devel-
opment of Epi-LumB and Epi-Basal tumors, including DZIP1
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 5 5 5e5 6 8566and COL4A2 (Epi-LumB) and TENC1 (Epi-Basal). In fact, CpG
promoter methylation of the TENC1 gene ranked among the
top scoring genes as a proxymarker for the Epi-Basal subtype.
The TENC1 gene (officially named tensin like C1 domain con-
taining phosphatase tensin 2) has not previously been identi-
fied as a tumor suppressor gene although it has been shown to
physically interact with DLC1 gene products (a well-
established tumor suppressor gene in liver cancer) through
which it contributes to growth suppression (Chan et al.,
2009). Likewise, none of the Epi-LumB specific markers, i.e.
ZNF132, TTBK1 and KCNA3 have been described as tumor sup-
pressors and it is not clear at this point whether epigenetic
inactivation of these genes represent driver events that
contribute to cancer development. Indeed, the possibility re-
mains that CpG island promoter methylation of these genes
may simply reflect the outcome of processes taking place on
a genome-wide scale. As an example, it has been suggested
that loss of protective barriers guarding CpG islands against
cytosine methylation are responsible for CpG island promoter
methylation in cancer; in which case PRC2-regulated genes
can simply be seen as more vulnerable than other genes for
CpG island promoter methylation as they are already targeted
for repression in normal cells. In this scenario, the vast major-
ity of CpG island promoter methylated genes represent pas-
senger events with only a few true cancer driving events
found in each case; in this context, DZIP1, COL4A2, L3MBTL4,
IRX1 and RASSF10 are named as likely candidates. Nonethe-
less, CpG island promoter methylation of the three Epi-
LumB proxy markers identified here (ZNF132, TTBK1 and
KCNA3) are more consistently observed across all tumors of
this subtype and thus more appropriate as proxies for identi-
fying tumors of this subtype regardless of whether they repre-
sent true cancer driving events or not.
The causative factors implicated in the methylator pheno-
type are currently emerging with exciting advances taking
place in gliomas following the identification of acquiredmuta-
tions in the IDH1 gene (Noushmehr et al., 2010). IDH1 muta-
tions were found to be correlated with high frequency of
CpG island methylation events in gliomas and subsequently
shown to be a causative factor in this regard (Noushmehr
et al., 2010; Turcan et al., 2012). More recently, the value of
IDH1 inhibitors has now been established in pre-clinical
models as a possible anti-cancer drug specifically active in
IDH1 mutated cancer cells leading to delayed growth and the
induction of differentiation (Rohle et al., 2013). However, the
IDH1 gene is rarely mutated in cancers other than gliomas
and is therefore not a likely candidate as a causative factor
for the CpG methylator phenotype in breast cancers
(Kandoth et al., 2013). Nevertheless, recent efforts aimed at
cancer genome sequencing have revealed recurrent muta-
tions in epigenetic genes, i.e. genes involved in regulating
chromatin dynamics and the processing of epigenetic marks
(Stephens et al., 2012; Cancer Genome Atlas Network, 2012).
Examples include mutations in the ARID1A gene occurring in
a subset of ovarian cancers (Jones et al., 2010) and breast can-
cers (Mamo et al., 2012) along with mutations in the MLL2,
MLL3, SMARCD1, NCOR1 and ARID1B genes found in a subset
of breast cancers (Stephens et al., 2012; Cancer Genome
Atlas Network, 2012; Kandoth et al., 2013). The distinct DNA
methylation signatures we describe can be a greatcomplement to the recently described genetic and expression
(Stephens et al., 2012; Curtis et al., 2012; Dvinge et al., 2013)
profiles to translate genomic analyses to clinical applications
in breast cancer.5. Conclusions
Breast cancer is a heterogenous disease with different sub-
types showing distinct biological and clinical features. An
important problem in breast cancer treatment is the definition
of patient subsets that will require aggressive treatment op-
tions and close follow-up after treatment. By studying the
DNA methylation landscape of breast cancers, we have
discovered signatures associated with two biologically
distinct and aggressive breast cancer subtypes known as
Basal-like and Luminal-B. The identified signatures underlie
the definition of two novel DNA methylation-based subtypes
referred to here as Epi-Basal and Epi-LumB, respectively. We
show that the DNA methylation defined subtypes hold prog-
nostic value that could provide helpful information beyond
that of other clinical parameters for making decisions on
whether or not cytotoxic therapy will be necessary. In this
context, we show that only a few selected proxy markers are
sufficient to classify tumors according to DNA methylation-
based subtypes using a cost-effective method and therefore
easily incorporated into the clinic.Financial support
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